JP2017514501A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017514501A5 JP2017514501A5 JP2016566656A JP2016566656A JP2017514501A5 JP 2017514501 A5 JP2017514501 A5 JP 2017514501A5 JP 2016566656 A JP2016566656 A JP 2016566656A JP 2016566656 A JP2016566656 A JP 2016566656A JP 2017514501 A5 JP2017514501 A5 JP 2017514501A5
- Authority
- JP
- Japan
- Prior art keywords
- rodent
- gene
- exon
- human
- modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000283984 Rodentia Species 0.000 claims description 218
- 108090000978 Interleukin-4 Proteins 0.000 claims description 103
- 108090000623 proteins and genes Proteins 0.000 claims description 75
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 60
- 102000004388 Interleukin-4 Human genes 0.000 claims description 57
- 239000012634 fragment Substances 0.000 claims description 45
- 238000000034 method Methods 0.000 claims description 41
- 101001033312 Homo sapiens Interleukin-4 receptor subunit alpha Proteins 0.000 claims description 39
- 230000001105 regulatory effect Effects 0.000 claims description 38
- 108091081024 Start codon Proteins 0.000 claims description 35
- 101100232919 Homo sapiens IL4 gene Proteins 0.000 claims description 27
- 230000014509 gene expression Effects 0.000 claims description 16
- 102000004169 proteins and genes Human genes 0.000 claims description 16
- 238000006467 substitution reaction Methods 0.000 claims description 15
- 101001002709 Homo sapiens Interleukin-4 Proteins 0.000 claims description 12
- 108700024394 Exon Proteins 0.000 claims description 11
- 102000055229 human IL4 Human genes 0.000 claims description 11
- 101100232925 Mus musculus Il4 gene Proteins 0.000 claims description 10
- 239000005557 antagonist Substances 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 8
- 201000004624 Dermatitis Diseases 0.000 claims description 6
- 108040006852 interleukin-4 receptor activity proteins Proteins 0.000 claims description 6
- 206010035664 Pneumonia Diseases 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000012216 screening Methods 0.000 claims description 4
- 241000699670 Mus sp. Species 0.000 claims description 3
- 230000001086 cytosolic effect Effects 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 108020004414 DNA Proteins 0.000 claims 8
- 238000001467 acupuncture Methods 0.000 claims 1
- 238000012239 gene modification Methods 0.000 claims 1
- 230000005017 genetic modification Effects 0.000 claims 1
- 235000013617 genetically modified food Nutrition 0.000 claims 1
- 210000001161 mammalian embryo Anatomy 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 description 24
- 108091028043 Nucleic acid sequence Proteins 0.000 description 20
- 101001033311 Mus musculus Interleukin-4 receptor subunit alpha Proteins 0.000 description 18
- 101001002703 Mus musculus Interleukin-4 Proteins 0.000 description 7
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 241001529936 Murinae Species 0.000 description 3
- 101100460719 Mus musculus Noto gene Proteins 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000011577 humanized mouse model Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461989757P | 2014-05-07 | 2014-05-07 | |
| US61/989,757 | 2014-05-07 | ||
| PCT/US2015/029638 WO2015171861A1 (en) | 2014-05-07 | 2015-05-07 | Humanized il-4 and il-4r alpha animals |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019235722A Division JP6838131B2 (ja) | 2014-05-07 | 2019-12-26 | ヒト化ＩＬ−４およびＩＬ−４Ｒα動物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017514501A JP2017514501A (ja) | 2017-06-08 |
| JP2017514501A5 true JP2017514501A5 (enExample) | 2018-05-24 |
| JP6640740B2 JP6640740B2 (ja) | 2020-02-05 |
Family
ID=53284509
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016566656A Active JP6640740B2 (ja) | 2014-05-07 | 2015-05-07 | ヒト化ＩＬ−４およびＩＬ−４Ｒα動物 |
| JP2019235722A Active JP6838131B2 (ja) | 2014-05-07 | 2019-12-26 | ヒト化ＩＬ−４およびＩＬ−４Ｒα動物 |
| JP2021019538A Active JP7145250B2 (ja) | 2014-05-07 | 2021-02-10 | ヒト化ＩＬ－４およびＩＬ－４Ｒα動物 |
| JP2022147925A Pending JP2022171841A (ja) | 2014-05-07 | 2022-09-16 | ヒト化ＩＬ－４およびＩＬ－４Ｒα動物 |
| JP2024150803A Active JP7755699B2 (ja) | 2014-05-07 | 2024-09-02 | ヒト化ＩＬ－４およびＩＬ－４Ｒα動物 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019235722A Active JP6838131B2 (ja) | 2014-05-07 | 2019-12-26 | ヒト化ＩＬ−４およびＩＬ−４Ｒα動物 |
| JP2021019538A Active JP7145250B2 (ja) | 2014-05-07 | 2021-02-10 | ヒト化ＩＬ－４およびＩＬ－４Ｒα動物 |
| JP2022147925A Pending JP2022171841A (ja) | 2014-05-07 | 2022-09-16 | ヒト化ＩＬ－４およびＩＬ－４Ｒα動物 |
| JP2024150803A Active JP7755699B2 (ja) | 2014-05-07 | 2024-09-02 | ヒト化ＩＬ－４およびＩＬ－４Ｒα動物 |
Country Status (26)
| Country | Link |
|---|---|
| US (7) | US9565841B2 (enExample) |
| EP (3) | EP3027015B1 (enExample) |
| JP (5) | JP6640740B2 (enExample) |
| KR (2) | KR102517112B1 (enExample) |
| CN (2) | CN110269047B (enExample) |
| AU (3) | AU2015255977B2 (enExample) |
| BR (1) | BR112016025745A2 (enExample) |
| CA (2) | CA2947307C (enExample) |
| CY (2) | CY1119773T1 (enExample) |
| DK (2) | DK3281521T3 (enExample) |
| ES (2) | ES2887852T3 (enExample) |
| HR (2) | HRP20180242T1 (enExample) |
| HU (2) | HUE055860T2 (enExample) |
| IL (3) | IL297105B2 (enExample) |
| LT (2) | LT3281521T (enExample) |
| MX (1) | MX370672B (enExample) |
| NO (1) | NO2785538T3 (enExample) |
| PH (1) | PH12016502058A1 (enExample) |
| PL (2) | PL3027015T3 (enExample) |
| PT (2) | PT3027015T (enExample) |
| RS (2) | RS62345B1 (enExample) |
| RU (1) | RU2703139C2 (enExample) |
| SG (2) | SG11201608570YA (enExample) |
| SI (2) | SI3027015T1 (enExample) |
| SM (2) | SMT202100560T1 (enExample) |
| WO (1) | WO2015171861A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2785538T3 (enExample) * | 2014-05-07 | 2018-08-04 | ||
| SG11201609638RA (en) | 2014-06-19 | 2016-12-29 | Regeneron Pharma | Non-human animals having a humanized programmed cell death 1 gene |
| KR102422356B1 (ko) * | 2014-09-17 | 2022-07-18 | 오를리콘 서피스 솔루션스 아크티엔게젤샤프트, 페피콘 | 내마모성이 향상된 이중층 코팅 절삭 공구의 제조 방법 |
| PL3223605T3 (pl) | 2014-11-24 | 2021-04-19 | Regeneron Pharmaceuticals, Inc. | Zwierzęta inne niż ludzie eksprymujące humanizowany kompleks CD3 |
| DK3466255T3 (da) | 2014-12-05 | 2021-05-03 | Regeneron Pharma | Ikke-humane dyr med en humaniseret klynge af differentiering af 47-gen |
| ES2841353T3 (es) | 2014-12-09 | 2021-07-08 | Regeneron Pharma | Animales no humanos que tienen un gen del grupo de diferenciación 274 humanizado |
| HUE054612T2 (hu) | 2015-11-20 | 2021-09-28 | Regeneron Pharma | Humanizált limfocitaaktiváló gén 3-t tartalmazó nem-humán állatok |
| US10582702B2 (en) | 2016-02-04 | 2020-03-10 | Regeneron Pharmaceuticals, Inc. | Non-human animals having an engineered ANGPTL8 gene |
| SG10202001578RA (en) * | 2016-02-29 | 2020-04-29 | Regeneron Pharma | Rodents having a humanized tmprss gene |
| TWI857389B (zh) * | 2016-12-01 | 2024-10-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
| KR102751957B1 (ko) | 2017-04-13 | 2025-01-09 | 리제너론 파마슈티칼스 인코포레이티드 | Il33 및 il1rl1을 코딩하는 유전자에서의 위험 대립유전자를 갖는 환자에서의 폐 질환의 치료 및 저해 |
| CN118994394A (zh) | 2017-06-12 | 2024-11-22 | 蓝鳍生物医药公司 | 抗-il1rap抗体和抗体药物缀合物 |
| CA3071712C (en) | 2017-09-29 | 2023-02-14 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ttr locus and methods of use |
| US11419318B2 (en) | 2017-11-30 | 2022-08-23 | Regeneran Pharmaceuticals, Inc. | Genetically modified rat comprising a humanized TRKB locus |
| JP7328243B2 (ja) | 2018-03-26 | 2023-08-16 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 治療薬を試験するためのヒト化げっ歯類 |
| IL277890B2 (en) | 2018-04-11 | 2024-03-01 | Regeneron Pharma | Methods for quantifying il-33 |
| JP7048051B2 (ja) | 2018-07-11 | 2022-04-05 | 正徳 染井 | 痒みを軽減するアトピー性皮膚炎治療剤 |
| SG11202011284RA (en) | 2018-07-16 | 2020-12-30 | Regeneron Pharma | Non-human animal models of ditra disease and uses thereof |
| CN111057721B (zh) * | 2018-10-12 | 2021-03-16 | 百奥赛图(北京)医药科技股份有限公司 | 人源化IL-4和/或IL-4Rα改造动物模型的制备方法及应用 |
| CN114164177A (zh) * | 2019-01-17 | 2022-03-11 | 百奥赛图(北京)医药科技股份有限公司 | 人源化转基因动物 |
| CN117178959A (zh) | 2019-04-04 | 2023-12-08 | 瑞泽恩制药公司 | 包括人源化凝血因子12基因座的非人动物 |
| JP7610339B2 (ja) | 2019-06-04 | 2025-01-08 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ベータスリップ変異を有するヒト化ｔｔｒ遺伝子座を含む非ヒト動物と使用方法 |
| BR112021022722A2 (pt) | 2019-06-07 | 2022-01-04 | Regeneron Pharma | Animal não humano, célula de animal não humana, genoma de animal não humano, gene de albumina animal não humana humanizada, vetor de alvejamento, método de avaliação da atividade de um reagente, e, método de otimização da atividade de um reagente |
| US20220272953A1 (en) * | 2019-07-29 | 2022-09-01 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animal with human or chimeric il33 |
| US20220312749A1 (en) * | 2019-08-09 | 2022-10-06 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animal with human or chimeric il2ra |
| CN112779285B (zh) * | 2019-11-11 | 2023-01-06 | 百奥赛图(北京)医药科技股份有限公司 | 人源化il-10和il-10ra基因改造动物的构建方法和应用 |
| US20220354097A1 (en) * | 2019-12-25 | 2022-11-10 | Gempharmatech Co., Ltd. | Il-15 humanized mouse model and use thereof |
| KR20220133248A (ko) * | 2020-01-28 | 2022-10-04 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화 pnpla3 좌위를 포함하는 비-인간 동물 및 사용 방법 |
| CN111149767B (zh) * | 2020-02-24 | 2021-07-20 | 中南大学湘雅二医院 | 一种人源化皮肤型红斑狼疮小鼠模型的构建方法和应用 |
| CN113527485B (zh) * | 2020-04-17 | 2024-11-15 | 湖南麦济生物技术股份有限公司 | 抗人白细胞介素-4受体α抗体及其制备方法和应用 |
| CN111808882B (zh) * | 2020-09-01 | 2020-12-29 | 北京百奥赛图基因生物技术有限公司 | Il7r基因人源化改造的动物模型的构建方法及其应用 |
| CN111793646B (zh) * | 2020-09-08 | 2021-01-15 | 北京百奥赛图基因生物技术有限公司 | Il1r1基因人源化改造的非人动物的构建方法及其应用 |
| CN111926039B (zh) * | 2020-09-23 | 2021-03-16 | 百奥赛图(北京)医药科技股份有限公司 | Il-13基因人源化的非人动物的构建方法和应用 |
| WO2022140221A1 (en) * | 2020-12-21 | 2022-06-30 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized tslp gene, a humanized tslp receptor gene, and/or a humanized il7ra gene |
| WO2022247936A1 (en) * | 2021-05-28 | 2022-12-01 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animal with human or chimeric cd36 |
| WO2024067796A1 (zh) * | 2022-09-28 | 2024-04-04 | 百奥赛图(北京)医药科技股份有限公司 | 一种il5和/或il5ra基因人源化修饰的非人动物 |
| IL322030A (en) * | 2023-01-11 | 2025-09-01 | Regeneron Pharma | Methods and systems for automated regulatory compliance testing |
| WO2025175099A1 (en) | 2024-02-16 | 2025-08-21 | Regeneron Pharmaceuticals, Inc. | A rodent copd model |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990005183A1 (en) * | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
| US6596541B2 (en) * | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| ES2667169T3 (es) | 2004-10-19 | 2018-05-09 | Regeneron Pharmaceuticals, Inc. | Método para generar un animal no humano homocigótico para una modificación genética |
| JP2007252370A (ja) * | 2006-02-22 | 2007-10-04 | Institute Of Physical & Chemical Research | Ｉｌ−４初期発現系トランスジェニック非ヒト動物およびその利用 |
| US7608693B2 (en) * | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| US20110016543A1 (en) * | 2008-12-04 | 2011-01-20 | Sigma-Aldrich Co. | Genomic editing of genes involved in inflammation |
| US20120157667A1 (en) * | 2009-06-29 | 2012-06-21 | Qingfeng Chen | Methods Of Producing Humanized Non-Human Mammals |
| JP2013500018A (ja) * | 2009-07-24 | 2013-01-07 | シグマ−アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニー | ゲノム編集のための方法 |
| RU2425880C2 (ru) * | 2009-07-30 | 2011-08-10 | Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН | Способ получения трансгенных мышей |
| ES2700852T3 (es) | 2009-10-06 | 2019-02-19 | Regeneron Pharma | Ratones modificados genéticamente e injerto |
| CN105861553B (zh) * | 2011-02-15 | 2020-08-14 | 再生元制药公司 | 人源化m-csf小鼠 |
| DK2663575T3 (en) * | 2011-10-28 | 2014-12-15 | Regeneron Pharma | HUMANIZED IL-6 and IL-6 receptor |
| KR102113108B1 (ko) | 2011-10-28 | 2020-05-20 | 리제너론 파아마슈티컬스, 인크. | 키메라 주요 조직적합성 복합체 （ｍｈｃ） 제ｉｉ부류 분자들을 발현하는 유전자전이 마우스 |
| HUE035652T2 (en) | 2011-10-28 | 2018-05-28 | Regeneron Pharma | Genetically modified major histocompatibility complex mice |
| US8962913B2 (en) | 2012-06-18 | 2015-02-24 | Regeneron Pharmaceuticals, Inc. | Humanized IL-7 rodents |
| ES2701093T3 (es) * | 2012-08-21 | 2019-02-20 | Sanofi Biotechnology | Métodos para tratar o prevenir el asma administrando un antagonista de IL-4R |
| IL307969B1 (en) | 2012-09-07 | 2025-10-01 | Regeneron Pharma | Genetically modified non-human animals and methods of using them |
| CA2887706C (en) | 2012-11-05 | 2022-08-02 | Regeneron Pharmaceuticals | Genetically modified non-human animals and methods of use thereof |
| WO2014130671A1 (en) | 2013-02-20 | 2014-08-28 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized t-cell co-receptors |
| KR102211267B1 (ko) | 2013-02-22 | 2021-02-04 | 리제너론 파아마슈티컬스, 인크. | 사람화된 주요 조직적합성 복합체를 발현하는 마우스 |
| JO3532B1 (ar) | 2013-03-13 | 2020-07-05 | Regeneron Pharma | الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها |
| RU2018136614A (ru) | 2013-09-23 | 2018-11-27 | Регенерон Фармасьютикалс, Инк. | Отличные от человека животные с гуманизированным геном сигнального регуляторного белка |
| TR201904342T4 (tr) | 2013-10-15 | 2019-05-21 | Regeneron Pharma | Hümani̇ze il-15 hayvanlar |
| EP3071024B1 (en) | 2013-11-19 | 2018-09-05 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized b-cell activating factor gene |
| AU2014353347B2 (en) | 2013-11-19 | 2020-07-02 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized a proliferation-inducing ligand gene |
| ES2794942T3 (es) | 2014-04-08 | 2020-11-19 | Regeneron Pharma | Animales no humanos que tienen receptores Fc-gamma humanizados |
| CA2946412C (en) | 2014-05-05 | 2024-02-27 | Regeneron Pharmaceuticals, Inc. | Humanized c5 and c3 animals |
| NO2785538T3 (enExample) | 2014-05-07 | 2018-08-04 |
-
2012
- 2012-11-22 NO NO12794266A patent/NO2785538T3/no unknown
-
2015
- 2015-05-07 IL IL297105A patent/IL297105B2/en unknown
- 2015-05-07 SM SM20210560T patent/SMT202100560T1/it unknown
- 2015-05-07 EP EP15727106.5A patent/EP3027015B1/en active Active
- 2015-05-07 KR KR1020227041893A patent/KR102517112B1/ko active Active
- 2015-05-07 HR HRP20180242TT patent/HRP20180242T1/hr unknown
- 2015-05-07 IL IL248358A patent/IL248358B2/en unknown
- 2015-05-07 LT LTEP17193855.8T patent/LT3281521T/lt unknown
- 2015-05-07 IL IL304841A patent/IL304841B1/en unknown
- 2015-05-07 BR BR112016025745-6A patent/BR112016025745A2/pt not_active Application Discontinuation
- 2015-05-07 EP EP17193855.8A patent/EP3281521B1/en active Active
- 2015-05-07 US US14/706,319 patent/US9565841B2/en active Active
- 2015-05-07 SM SM20180018T patent/SMT201800018T1/it unknown
- 2015-05-07 RU RU2016143376A patent/RU2703139C2/ru active
- 2015-05-07 MX MX2016014563A patent/MX370672B/es active IP Right Grant
- 2015-05-07 PT PT157271065T patent/PT3027015T/pt unknown
- 2015-05-07 HU HUE17193855A patent/HUE055860T2/hu unknown
- 2015-05-07 HR HRP20211455TT patent/HRP20211455T1/hr unknown
- 2015-05-07 PT PT171938558T patent/PT3281521T/pt unknown
- 2015-05-07 ES ES17193855T patent/ES2887852T3/es active Active
- 2015-05-07 KR KR1020167034170A patent/KR102473565B1/ko active Active
- 2015-05-07 LT LTEP15727106.5T patent/LT3027015T/lt unknown
- 2015-05-07 RS RS20211141A patent/RS62345B1/sr unknown
- 2015-05-07 SI SI201530162T patent/SI3027015T1/en unknown
- 2015-05-07 DK DK17193855.8T patent/DK3281521T3/da active
- 2015-05-07 SG SG11201608570YA patent/SG11201608570YA/en unknown
- 2015-05-07 WO PCT/US2015/029638 patent/WO2015171861A1/en not_active Ceased
- 2015-05-07 RS RS20180131A patent/RS57073B1/sr unknown
- 2015-05-07 HU HUE15727106A patent/HUE038028T2/hu unknown
- 2015-05-07 SI SI201531703T patent/SI3281521T1/sl unknown
- 2015-05-07 SG SG10201912354PA patent/SG10201912354PA/en unknown
- 2015-05-07 JP JP2016566656A patent/JP6640740B2/ja active Active
- 2015-05-07 AU AU2015255977A patent/AU2015255977B2/en active Active
- 2015-05-07 PL PL15727106T patent/PL3027015T3/pl unknown
- 2015-05-07 CN CN201910691834.4A patent/CN110269047B/zh active Active
- 2015-05-07 EP EP21166663.1A patent/EP3906781A1/en active Pending
- 2015-05-07 CA CA2947307A patent/CA2947307C/en active Active
- 2015-05-07 CN CN201580036907.6A patent/CN106470545B/zh active Active
- 2015-05-07 ES ES15727106.5T patent/ES2656529T3/es active Active
- 2015-05-07 CA CA3207834A patent/CA3207834C/en active Active
- 2015-05-07 PL PL17193855T patent/PL3281521T3/pl unknown
- 2015-05-07 DK DK15727106.5T patent/DK3027015T3/en active
- 2015-07-06 US US14/791,978 patent/US9743647B2/en active Active
-
2016
- 2016-10-17 PH PH12016502058A patent/PH12016502058A1/en unknown
-
2017
- 2017-07-14 US US15/649,702 patent/US10588298B2/en active Active
- 2017-09-15 US US15/705,326 patent/US10477842B2/en active Active
-
2018
- 2018-01-15 CY CY20181100040T patent/CY1119773T1/el unknown
-
2019
- 2019-10-07 US US16/594,537 patent/US11109578B2/en active Active
- 2019-12-26 JP JP2019235722A patent/JP6838131B2/ja active Active
-
2021
- 2021-02-10 JP JP2021019538A patent/JP7145250B2/ja active Active
- 2021-08-05 US US17/394,492 patent/US11963521B2/en active Active
- 2021-08-18 AU AU2021218060A patent/AU2021218060C1/en active Active
- 2021-09-14 CY CY20211100805T patent/CY1124605T1/el unknown
-
2022
- 2022-08-30 US US17/823,186 patent/US12310340B2/en active Active
- 2022-09-16 JP JP2022147925A patent/JP2022171841A/ja active Pending
-
2024
- 2024-07-08 AU AU2024204694A patent/AU2024204694A1/en active Pending
- 2024-09-02 JP JP2024150803A patent/JP7755699B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017514501A5 (enExample) | ||
| JP7755699B2 (ja) | ヒト化ＩＬ－４およびＩＬ－４Ｒα動物 | |
| He et al. | Hepatitis D virus infection of mice expressing human sodium taurocholate co-transporting polypeptide | |
| US10655144B2 (en) | Nucleic acid construct with a p16 promoter that causes a prodrug converting enzyme to be expressed specifically in senescent cells | |
| JP2019047818A5 (enExample) | ||
| RU2648166C1 (ru) | Животные, содержащие гуманизированную дипептидилпептидазу iv (dpp4) | |
| JP2018500896A5 (enExample) | ||
| JP2011501652A5 (enExample) | ||
| HRP20251062T1 (hr) | Neljudske životinje koje imaju gen humaniziranog proteina za reguliranje signala | |
| JP2017213006A5 (enExample) | ||
| JP2020510418A5 (enExample) | ||
| ES2908669T3 (es) | Animales no humanos que tienen un gen ANGPTL8 modificado genéticamente | |
| JP2019511918A5 (enExample) | ||
| JP2019506897A5 (enExample) | ||
| JP2019505216A5 (enExample) | ||
| JP2020515248A5 (enExample) | ||
| US20220192165A1 (en) | Non-human animals having a humanized tslp gene, a humanized tslp receptor gene, and/or a humanized il7ra gene | |
| JP2018500882A5 (enExample) | ||
| RU2788523C2 (ru) | ЖИВОТНЫЕ С ГУМАНИЗИРОВАННЫМИ IL-4 И IL-4Rα | |
| Araya et al. | Interferon signaling modulates Down syndrome-associated Alzheimer’s disease pathology in a mouse model | |
| CN118581158A (zh) | 一种限制型心肌病动物模型的构建方法 | |
| RU2020135272A (ru) | Модели заболевания ditra на животных, отличных от человека, и пути их применения | |
| CN110564771A (zh) | 脑钙化病模型的制备方法 | |
| JP2005087164A (ja) | ノックアウトマウス | |
| HK1245011A1 (en) | Humanized il-4 and il-4r alpha animals |